Exact Sciences focuses on cancer screening and long-term growth
Exact Sciences is a molecular diagnostics company specializing in cancer screening and detection, with a strategic focus on expanding its role in global healthcare through non-invasive testing. The company's business model relies on recurring revenue from diagnostic tests, supported by insurance coverage and physician adoption. Exact Sciences invests significantly in R&D to enhance test accuracy and explore new applications, aiming to strengthen its position in precision medicine and early cancer detection.
Exact Sciences outlines long term diagnostics growth as cancer screening demand expands
Exact Sciences is strategically positioning its diagnostics portfolio for sustained growth by focusing on colorectal and multi-cancer screening. The company emphasizes early cancer detection to improve outcomes and reduce healthcare costs, supported by investments in clinical studies and data. Their diversified approach includes precision oncology, offering tests for tumor characterization and treatment guidance, aiming for broader clinical adoption and stable reimbursement.
The Cologuard test - Exact Sciences leans on at-home colon cancer screening
Exact Sciences' Cologuard test offers an FDA-approved, at-home stool DNA screening for colorectal cancer in average-risk adults aged 45 and older. It provides a non-invasive alternative to an initial colonoscopy, with high sensitivity for detecting cancer and precancerous lesions, and is widely covered by insurance as a preventive service. The test's accessibility and ease of use are key to its success, addressing patient hesitancy towards traditional screening methods.
If You Invested $1,000 in Exact Sciences Corp (EXAS)
This article analyzes the historical performance of a hypothetical $1,000 investment in Exact Sciences Corp (EXAS) over various periods, showing significant returns over 1 and 10 years but a loss over 5 years. It details Exact Sciences' business as a leading provider of cancer screening and diagnostic tests, including Cologuard and Oncotype DX, and mentions a proposed merger agreement with Abbott Laboratories. The article also provides a year-by-year return comparison of EXAS against the S&P 500.
Exact Sciences focuses on cancer diagnostics as investors track its long term growth prospects
Exact Sciences is a molecular diagnostics company specializing in cancer screening and detection, developing laboratory tests to identify cancer early. The company's business model relies on diagnostic tests processed in centralized laboratories and focuses on expanding its portfolio through R&D, with its colorectal cancer screening test being a central product. Investors monitor Exact Sciences' growth prospects, research investments, and the balance between revenue growth and profitability, recognizing the influence of health policy and reimbursement frameworks on the stock.
Exact Sciences Corp outlines growth ambitions as cancer screening demand expands
Exact Sciences Corp is expanding its core cancer screening business and pursuing long-term growth in diagnostic testing and precision medicine. The company focuses on laboratory-developed tests for early disease detection, with a primary product being a non-invasive colorectal cancer screening test. Its strategy involves broadening its test portfolio to include other cancers and investing in advanced molecular techniques to improve test performance.
Exact Sciences holds steady as investors await a fresh catalyst
Exact Sciences (EXAS) is a cancer diagnostics company whose stock is trading without a new market-moving catalyst. The article highlights the company's focus on execution, operational discipline, and penetration of screening programs for its noninvasive cancer screening and precision oncology tests, including Cologuard. Investors are awaiting further updates from filings, earnings, or new operational disclosures.
Exact Sciences focuses on cancer diagnostics as investors weigh long-term growth
Exact Sciences Corp. is a diagnostics company specializing in cancer screening and testing, with its revenue tied to the adoption of its proprietary tests. The company's growth outlook is linked to an aging population, policy decisions, and its ability to introduce new tests and expand existing ones. Investors analyze factors like revenue growth, operating margin trends, and research spending, comparing the company to other diagnostic and life science firms.
Exact Sciences opens the week with a clear earnings calendar, shares on NASDAQ in focus
Exact Sciences is preparing for its Q2 2026 earnings report, expected in late July, with investors closely watching its cancer diagnostics business. Analysts anticipate continued growth in colorectal cancer screening and genomic testing. The company's shares are traded on NASDAQ, and key products include Cologuard and Oncotype DX.
Exact Sciences background and strategy, shares on NASDAQ in a diagnostics peer view
Exact Sciences specializes in cancer diagnostics, particularly known for its non-invasive Cologuard test for colorectal cancer screening. The article discusses the company's growth strategy, including portfolio expansion beyond colorectal cancer and strategic acquisitions, positioning it among US diagnostics peers on NASDAQ. It also covers the economic aspects of cancer screening, recurring revenue streams, and the company's commitment to R&D and regulatory compliance.
Labcorp rolls out colorectal cancer screening test nationwide
Labcorp has launched its ColoSense colorectal cancer screening test nationwide, positioning it as a competitor to Exact Sciences' Cologuard. The rollout follows CMS approval for coverage and the American Cancer Society's endorsement. ColoSense differentiates itself with a simplified stool collection process, addressing user discomfort associated with Cologuard's method.
Exact Sciences Corp (EXAS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Exact Sciences Corp (EXAS), highlighting its current price momentum score of 6.38, ranking it 245 out of 392 in its industry. It details the stock's trading range between resistance at $105.61 and support at $103.58, suggesting suitability for range-bound swing trading. The analysis includes a breakdown of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, concluding with a "Buy" signal based on these metrics.
Exact Sciences Stock - Analyst consensus and valuation snapshot
Exact Sciences (US30063P1057) is a US-based cancer diagnostics specialist that continues to receive positive opinions from Wall Street analysts, with a predominance of Buy and Overweight ratings. Analysts anticipate double-digit revenue growth and near break-even adjusted earnings for the current fiscal year, driven by the large addressable market in cancer screening. Although some price targets have been trimmed, the average 12-month price target still suggests upside from the current share price.
Exact Sciences Stock - Sunday background on the cancer diagnostics pioneer
Exact Sciences, a molecular diagnostics company, is highlighted for its role in cancer screening, particularly with its non-invasive colorectal cancer test. The article provides a detailed background on its business model, competitive landscape, financial profile, and growth drivers like reimbursement and international expansion. It also touches on the company's technology, innovation pipeline, and management's focus on clinical rigor and commercialization, noting its position in the healthcare ecosystem.
Exact Sciences Stock - Sunday background on the cancer diagnostics pioneer
This article provides a background on Exact Sciences (EXAS), a molecular diagnostics company known for its non-invasive colorectal cancer screening test, Cologuard. It covers the company's business model, competitive landscape, financial profile, and growth drivers, including reimbursement and clinical guidelines. The piece also touches on regulatory requirements, management priorities, international expansion, and technological innovations in its oncology portfolio.
Why Cologuard from Exact Sciences is quietly changing at-home cancer screening
Cologuard by Exact Sciences is transforming at-home colorectal cancer screening by offering a non-invasive, convenient alternative to colonoscopies. This stool-based test detects cancer and precancerous lesions early, making it a valuable option for individuals hesitant about traditional screening methods. The article details its effectiveness, integration into healthcare workflows, and market presence, primarily in the U.S.
Exact Sciences Stock - Analyst sentiment and technical picture on Thursday
Exact Sciences (EXAS) stock is trading near its recent highs, with a current market capitalization of approximately $20 billion. Analyst sentiment is mixed but generally constructive, with a consensus "Reduce" rating and an average 12-month price target near $92, implying potential downside from current levels. The company, known for its Cologuard and Oncotype DX products, shows a robust upward trend based on technical indicators, trading above its 50-day range midpoint and longer-term moving averages.
Exact Sciences Corp (EXAS) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Exact Sciences Corp (EXAS). The company's current valuation score is 7.55, ranking 100 out of 392 in its industry. Notably, its P/E ratio is -95.19, significantly below its recent high, while P/B, P/S, and P/CF data have not been disclosed.
Exact Sciences Corp. Stock (US30063P1057): shares in focus amid quiet newsflow
Exact Sciences Corp. shares are trading in a narrow range without significant new earnings or rating triggers, keeping the focus on its valuation and position in the U.S. diagnostics sector. The company primarily targets cancer screening and diagnostics, particularly with its Cologuard test, and is noted for its role in precision oncology. Despite quiet near-term newsflow, investor attention remains on its fundamentals, long-term cancer-testing demand, reimbursement dynamics, and competitive landscape.
Exact Sciences Corp. Stock (US30063P1057): Technical picture in focus after recent volatility
Exact Sciences Corp. stock is primarily driven by technical and sentiment factors, with traders closely monitoring its performance within the diagnostics and cancer screening sector. Despite a lack of new corporate announcements, its Nasdaq listing and role in cancer screening keep it on the radar of investors, who are analyzing chart signals and peer actions in the broader U.S. healthcare market. The company's technical levels, such as moving averages and prior swing highs and lows, are crucial for short-term market participants assessing risk and opportunity.
Exact Sciences Corp. Stock (US30063P1057): valuation and fundamentals in focus after recent run-up
Exact Sciences Corp. has seen a significant rebound in its share price from 2024 lows, bringing its valuation and fundamentals back into focus for investors. The company, known for its Cologuard test, continues to be growth-oriented, with its valuation tied to revenue expansion in screening and precision oncology segments. Investors are examining profitability, balance sheet strength, and competitive landscape to assess the stock's future trajectory.
Exact Sciences Corp. stock (US30063P1057): earnings momentum and cancer screening growth in focus
Exact Sciences Corp. (EXAS) is a diagnostics company focused on non-invasive cancer screening, particularly colorectal cancer. The company's growth is driven by increasing adoption of its screening tests, progress in precision oncology, and the evolving reimbursement landscape. Investors monitor the company's financial performance, its ability to scale operations efficiently, and its competitive positioning within the rapidly innovating diagnostics market, especially given its strong tie to US healthcare policy and reimbursement decisions.
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings
This article provides a company profile for Exact Sciences (EXAS), including its stock performance, news, and rankings by Fortune. It highlights the company's recognition as a "Great Place to Work" in Biotechnology and Pharmaceuticals, citing positive employee feedback about the CEO's involvement and care for employees. The profile also touches on key financials and other rankings.
Exact Sciences Corp stock (US30063P1057): Nasdaq-listed cancer diagnostics group steady after recent
Exact Sciences shares remained largely stable on Nasdaq after a significant rebound, trading near their 52-week high with a market capitalization of approximately USD 20 billion. Investors are evaluating the company's growth prospects and valuation, which prioritizes revenue expansion and cash flow over immediate earnings, aligning with analyst price targets around USD 92. The company, known for its Cologuard test and precision oncology assays, focuses on molecular diagnostics for early cancer detection.
Exact Sciences Corp. stock (US30063P1057): Abbott buyout clouds listing status and sector role
Abbott's acquisition of Exact Sciences creates uncertainty for the stock's future as a standalone Nasdaq listing, despite its colorectal cancer screening franchise remaining central to the non-invasive diagnostics market. This deal reflects a broader industry trend of large diagnostics groups consolidating innovative molecular testing platforms. Investors may now gain exposure to Exact Sciences' assets primarily through Abbott's broader equity.
Exact Sciences Corp. stock (US30063P1057): Abbott deal reshapes outlook for cancer diagnostics leader
Exact Sciences Corp., known for its Cologuard test, has been acquired by Abbott in early 2026, integrating its cancer screening portfolio into Abbott's diagnostics business. This acquisition strengthens Abbott's oncology diagnostics sales and reshapes Exact Sciences' future from a standalone growth story to a core component of a diversified healthcare group. The continued clinical relevance of Cologuard is reinforced by updated American Cancer Society guidelines, supporting its potential contribution to Abbott’s growth.
Exact Sciences stock (US30063P1057): Diagnostics peer update after Petrichor hiring
Exact Sciences is gaining renewed market attention after its former CEO, Don Hardison, joined Petrichor as an operating partner. While not a direct company action, this move highlights the company's past leadership and the broader diagnostics sector, where sentiment is driven by reimbursement, test adoption, and commercial execution. Investors are encouraged to monitor future company-reported results and guidance for more significant insights rather than indirect industry headlines.
Exact Sciences stock (US30063P1057): screening business, oncology focus, and what U.S. investors are
Exact Sciences is a U.S. diagnostics company primarily known for its Cologuard colorectal cancer screening test and oncology-focused molecular testing. The company's investment appeal lies in the large addressable market for colorectal cancer screening and its diversified oncology segment. Investors are keenly watching the company's commercial execution, test adoption rates influenced by reimbursement and guidelines, and its ability to achieve sustainable profitability in the competitive diagnostics landscape.
Exact Sciences Corp. stock (US30063P1057): diagnostics specialist in focus after leadership news
Exact Sciences Corp., known for its Cologuard colorectal cancer screening test, is gaining renewed attention after its former CEO, Don Hardison, joined healthcare investor Petrichor. The company's business model focuses on developing and commercializing diagnostic tests for early cancer detection and precision oncology, with Cologuard being a primary revenue driver. Exact Sciences operates in a competitive and evolving diagnostics market, making its ability to innovate and navigate policy changes crucial for future performance.
Exact Sciences Corp. stock (US30063P1057): earnings backdrop and cancer diagnostics focus
Exact Sciences Corp. is drawing investor attention after its latest quarterly update, which highlighted continued growth in colorectal cancer screening revenue from its Cologuard product. The company operates in the molecular diagnostics sector, focusing on cancer detection and early screening, and is investing heavily in broader cancer diagnostics despite ongoing operating losses due to high research and marketing spending. The article also discusses market trends, competitive positioning, and risks for investors.
Exact Sciences Corp stock (US30063P1057): acquisition plans stir debate around growth and dilution
Exact Sciences Corp is set to acquire Abbott’s molecular diagnostics unit, a move that will expand its testing portfolio to include infectious disease and genetic testing alongside its current cancer diagnostics. While this acquisition broadens market reach and leverages existing infrastructure, it also introduces near-term earnings dilution and integration risks. Investors will be closely watching how the company manages these challenges and ultimately realizes the synergies from this strategic expansion.
Exact Sciences stock (US30063P1057): latest business update and investor focus
Exact Sciences remains a key company for US investors due to its focus on cancer screening and diagnostics, particularly in the colorectal cancer market. The company's performance is tied to test adoption, reimbursement coverage, and competitive execution. Investors monitor quarterly reports, payer decisions, and product rollouts for future catalysts, as its business model is strongly influenced by public health trends and commercial strategies.
Exact Sciences stock (US30063P1057): Screening leader faces a new investor test
Exact Sciences remains a significant diagnostics company for U.S. investors, primarily due to its leading colorectal cancer screening product, Cologuard. The company's future performance hinges on consistent adoption rates, stable reimbursement policies, and its ability to expand beyond its current product range. Investors are advised to monitor quarterly execution, test volume trends, and any updates to its growth projections.
Exact Sciences Corp. stock (US30063P1057): earnings beat and Abbott takeover reshape cancer diagnost
Exact Sciences Corp. reported stronger-than-expected quarterly results and has agreed to a multi-billion dollar takeover by Abbott, valued at around $21 billion. This acquisition is set to strengthen Abbott's cancer diagnostics portfolio and integrate Exact Sciences' molecular tests into Abbott's global distribution network. While Exact Sciences has strong growth prospects in colorectal cancer screening and precision oncology, it still operates with negative net margins, with the stock's performance driven by revenue growth and strategic value rather than current income.
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B
Exact Sciences Corp., a cancer screening technology leader, was acquired by Abbott Laboratories for $20.6 billion, consolidating control over the U.S. cancer screening market. The deal, completed on March 23, 2026, followed Exact Sciences missing its consensus EPS estimates in its latest quarterly earnings report, despite significant revenue growth. This acquisition highlights strategic shifts in the diagnostics sector and offers investors a potentially stable, defensive investment in healthcare.
Exact Sciences stock (US30063P1057): Q1 2026 revenue growth driven by Cologuard and Oncotype DX
Exact Sciences reported a strong Q1 2026 with $1.62 billion in revenue, marking a 12% year-over-year increase. This growth was primarily fueled by the robust performance of its cancer screening product, Cologuard, and its diagnostic test, Oncotype DX. The company is actively investing in pipeline expansion and strengthening its cash position to further its market share in the precision oncology diagnostics sector.
Exact Sciences Corp. stock (US30063P1057): Risk channels signal institutional focus
Exact Sciences Corp. (EXAS) stock is being driven by institutional models through its price action, influencing risk channels and allocation strategies. The company, known for its Cologuard cancer screening test, plays a significant role in US healthcare spending and preventive diagnostics. Its strong market position in colorectal cancer screening and expansion into other areas make it relevant for growth-oriented US investors.
Exact Sciences Corp. stock (US30063P1057): Q1 2026 earnings and screening advancements
Exact Sciences Corp. reported strong Q1 2026 financial results, with revenue reaching $1.62 billion, a 12% year-over-year increase, driven by Cologuard and Oncotype DX. The company's commitment to expanding non-invasive cancer screening, particularly with Cologuard Plus, continues to drive growth. These results highlight Exact Sciences' strong position in the precision oncology diagnostics sector, appealing to US investors.
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue up 23%
Exact Sciences Corp. reported a Q4 earnings miss, with earnings per share at -$0.21 against an estimated $0.08, but showed strong revenue growth of 23.1% year-over-year. The growth was driven primarily by its Cologuard product, a non-invasive colorectal cancer screening test, which accounts for over 80% of sales. Despite increased investments and an earnings miss, the company's focus on precision medicine and potential for market expansion in the US cancer screening market positions it as a significant player for investors.
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue growth
Exact Sciences Corp. reported Q4 earnings of -$0.21 per share, missing analyst estimates by $0.29, despite a 23.1% year-over-year revenue increase. The company, known for its Cologuard cancer screening test, demonstrates continued product adoption and R&D investment in the high-growth molecular diagnostics sector. While facing profitability challenges with a net margin of -6.40%, its market leadership in colorectal cancer screening and focus on early detection position it as a key player in the US healthcare market for investors.
Exact Sciences Corp. stock (US30063P1057): Q4 2025 earnings miss on EPS despite revenue beat
Exact Sciences Corp. reported its Q4 2025 earnings, missing EPS estimates with -$0.21, despite revenue rising 23.1% year-over-year to $878.38 million and beating forecasts. The company continues to show strong top-line growth driven by its cancer-screening portfolio, particularly Cologuard, while analysts anticipate a return to profitability in the next year. Exact Sciences, with a market cap of $20.03 billion, remains a growth-oriented healthcare stock with significant R&D investments.
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover
This article mentions that Exact Sciences (EXAS) stock fell in premarket trading despite analysts suggesting it could be a triple-digit acquisition target for Abbott (ABT). It notes that Baird reiterated an Outperform rating and $125 price target on EXAS after its earnings. The article also provides a brief overview of year-to-date performance for both companies.
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits
Exact Sciences Corporation (EXAS) stock hit a four-year high despite multiple Wall Street downgrades following its agreement to acquire Abbott Labs' Molecular Diagnostics business. The market's positive reaction to the acquisition, seen as a strategic move to boost revenue and improve market position, has led to significant gains for investors. Retail traders, however, appear to be taking profits, suggesting a potential short-term pullback after the surge.
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits
Exact Sciences stock reached a four-year high despite multiple downgrades from Wall Street analysts following its deal with Abbott. The stock's rise was attributed to optimism surrounding the Abbott deal, though retail traders reportedly took profits, leading to a slight dip. Analysts are cautious, citing potential competitive pressures and the terms of the Abbott diagnostic device deal.
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account
Representative Laura Friedman recently exchanged shares of Exact Sciences Corp for Abbott Laboratories through her Fidelity brokerage account. The transaction, valued between $1,001 and $15,000, was a result of a merger. Abbott Laboratories is currently viewed as undervalued by InvestingPro.
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account
Laura Friedman, representative for California's 30th congressional district, recently exchanged shares of Exact Sciences Corp (NASDAQ:EXAS) for Abbott Laboratories (NYSE:ABT) via her Fidelity brokerage account. The transaction, valued between $1,001 and $15,000, occurred due to a merger. Abbott Laboratories, a global healthcare company, is noted as potentially undervalued by InvestingPro analysis, despite the financial details and reasons behind Friedman's specific decision remaining undisclosed.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock sustained upside?
Exact Sciences Corp. leads the non-invasive cancer screening market with its Cologuard test, targeting colorectal cancer. The company's business model relies on widespread adoption and reimbursement, positioning it as a key player in preventive healthcare amidst increasing cancer rates globally. While analysts are generally positive due to strong clinical data and market leadership, investors should consider risks like reimbursement uncertainties, competition, and high R&D costs when evaluating its long-term growth potential and market valuation.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock sustained upside?
Exact Sciences Corp. leads the non-invasive cancer screening market, primarily with its Cologuard test, targeting a significant U.S. population for colorectal cancer detection. The company's business model relies on specialized diagnostics and recurring revenue from insurance-reimbursed lab services. While analysts generally hold a positive outlook due to strong clinical data and market adoption, investors should monitor risks such as reimbursement changes, R&D costs, and competition from emerging technologies.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock new upside?
Exact Sciences Corp. (US30063P1057) is a leader in non-invasive cancer screening, with its Cologuard product dominating colorectal cancer detection. The company's business model relies on recurring revenue from high-volume, non-invasive tests and strategic investments in automation. While Cologuard addresses a significant market, the company is also expanding into multi-cancer detection with products like CancerSEEK, targeting a broader oncology screening market.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock new upside?
Exact Sciences Corp. is a leader in non-invasive cancer screening, with its flagship Cologuard product dominating colorectal cancer detection. The company's business model relies on high-volume, non-invasive tests and aims to capture a larger share of the multi-billion-dollar U.S. cancer screening market. While it faces risks from reimbursement changes and competition, analysts remain positive due to Cologuard's strong adoption and pipeline potential, especially in multi-cancer detection.
